Traditional Chinese medicine in antiviral treatment

Hua Wang, Wang Qin, Jia-Yu Chen, Shi Guojuan, Chen Linwei
{"title":"Traditional Chinese medicine in antiviral treatment","authors":"Hua Wang, Wang Qin, Jia-Yu Chen, Shi Guojuan, Chen Linwei","doi":"10.53388/tmrim202004014","DOIUrl":null,"url":null,"abstract":"The Novel Coronavirus (COVID-19), which broke out in Wuhan, China in December 2019, attracted worldwide attention. With a long incubation period and strong infectiousness, COVID-19 poses a great threat to the life and health worldwide with high incidence, high pathogenicity and low sensitivity to antibiotics. At present, there are less kinds of antiviral drugs, including rimantadine hydiochloride, acyclovir, interferon, zidovudine, ribavirin, etc., which maybe lead to severe adverse reactions of the nervous system, hematopoietic system, liver and kidney system, as well as side effects such as nausea, vomiting, upper abdominal discomfort and diarrhea. Meanwhile, the development of antiviral drugs requires huge investment and time, the development of effective antiviral drugs and vaccine lags far behind the rapidly developed disease. Traditional Chinese medicine has played an important role against the infection, especially in the fight against severe acute respiratory syndrome, H1N1 influenza, H7N9 flu virus, middle east respiratory syndrome and Ebola virus infection. In this paper, the classification, mechanism, existing problems and the prospect of traditional Chinese medicine in antiviral treatment has been summarized in order to provide certain reference for the research and prescription screening of traditional Chinese medicine anti-COVID-19 drugs.","PeriodicalId":70680,"journal":{"name":"TMR整合医学","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"TMR整合医学","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.53388/tmrim202004014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The Novel Coronavirus (COVID-19), which broke out in Wuhan, China in December 2019, attracted worldwide attention. With a long incubation period and strong infectiousness, COVID-19 poses a great threat to the life and health worldwide with high incidence, high pathogenicity and low sensitivity to antibiotics. At present, there are less kinds of antiviral drugs, including rimantadine hydiochloride, acyclovir, interferon, zidovudine, ribavirin, etc., which maybe lead to severe adverse reactions of the nervous system, hematopoietic system, liver and kidney system, as well as side effects such as nausea, vomiting, upper abdominal discomfort and diarrhea. Meanwhile, the development of antiviral drugs requires huge investment and time, the development of effective antiviral drugs and vaccine lags far behind the rapidly developed disease. Traditional Chinese medicine has played an important role against the infection, especially in the fight against severe acute respiratory syndrome, H1N1 influenza, H7N9 flu virus, middle east respiratory syndrome and Ebola virus infection. In this paper, the classification, mechanism, existing problems and the prospect of traditional Chinese medicine in antiviral treatment has been summarized in order to provide certain reference for the research and prescription screening of traditional Chinese medicine anti-COVID-19 drugs.
中药抗病毒治疗
2019年12月在中国武汉爆发的新型冠状病毒(COVID-19)引起了全世界的关注。新型冠状病毒病具有高发病率、高致病性、对抗生素低敏感性等特点,潜伏期长,传染性强,对全球生命健康构成极大威胁。目前,抗病毒药物种类较少,包括盐酸金刚乙胺、阿昔洛韦、干扰素、齐多夫定、利巴韦林等,可能导致神经系统、造血系统、肝肾系统的严重不良反应,以及恶心、呕吐、上腹部不适、腹泻等副作用。同时,抗病毒药物的开发需要巨大的投入和时间,有效的抗病毒药物和疫苗的开发远远落后于疾病的快速发展。中医药在抗疫斗争中发挥了重要作用,特别是在抗击严重急性呼吸综合征、H1N1流感、H7N9流感、中东呼吸综合征、埃博拉病毒等疫情中发挥了重要作用。本文就中药在抗病毒治疗中的分类、作用机制、存在的问题及前景进行综述,以期为中药抗covid -19药物的研究和处方筛选提供一定的参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
83
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信